SHR-9839
PreclinicalSmall molecule
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-9839 is one of 4 small molecule programs targeting Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. It is currently in Preclinical.
1
Indications
5
Total Trials
5
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Recurrent/metastatic Head and Neck Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Preclinical
Erbitux
IImclone
Preclinical
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.Preclinical
SHR-9839
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Solid Tumors1 trial
NSCLC1 trial
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-9839. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details